LB PHARMACEUTICALS INC - LBRX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | RA Capital Management, L.P. | 8.7% | 2,208,604 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Peter Kolchinsky | 8.7% | 2,208,604 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Rajeev Shah | 8.7% | 2,208,604 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | RA Capital Healthcare Fund, L.P. | 8.7% | 2,208,604 | View |
| Feb 10, 2026 | SCHEDULE 13D/A | — | 9.99% | 28,605,673 | View |
| Jan 21, 2026 | SCHEDULE 13G | JPMORGAN CHASE & CO. | 6.3% | 1,611,482 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | BlackRock Portfolio Management LLC | 3.8% | 961,158 | View |
| Dec 31, 2025 | SCHEDULE 13G | Trails Edge Capital Partners, LP | 5.0% | 1,268,265 | View |
| Dec 31, 2025 | SCHEDULE 13G | Trails Edge Biotechnology Master Fund, LP | 5.0% | 1,268,265 | View |
| Dec 31, 2025 | SCHEDULE 13G | Ortav Yehudai | 5.0% | 1,268,265 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.